News
Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...
Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.
1h
Vietnam Investment Review on MSNWegovy® Now Available in Singapore for Weight ManagementSINGAPORE - Media OutReach Newswire - 12 July 2025 - A significant advancement in weight management has arrived for Singaporeans. Novo Nordisk, a global healthcare company focused on defeating serious ...
GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...
Researchers have determined in a new study that the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower the risk of ...
19h
News-Medical.Net on MSNHigher protein intake may help prevent muscle loss in semaglutide usersWomen and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein intake may help prevent muscle loss in these patients, according to a small ...
A FAT jab user has revealed that after stopping the injections for eight weeks, she has now realised she is a “Mounjaro lifer ...
SIGNIFICANT EVENTS DURING 1 APRIL - 30 JUNE 2025In April, Iconovo announced an organizational change expected to reduce annual costs by approximately 14-16 MSEK starting in the third quarter of 2025.
New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...
Though long-term prospects appear sound, near-term earnings visibility remains limited for Dr. Reddy's Labs, Cipla, and Lupin ...
New study published by Truveta and Harvard Medical School A groundbreaking study published today in Pediatrics Open Science ...
Scientists have gene-hacked mice to produce their own Ozempic-like drugs, paving a path for humans to do so themselves one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results